Organisation paid for research Program year 2025 Source: CMS Open Payments

Lakeview Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,048,519

103 payments

Through program year 2025, Lakeview Clinical Research is reported as receiving $3,048,519 in research payments, across 103 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $268,982 39
2024 Research $1,013,039 26
2023 Research $1,708,097 33
2022 Research $58,402 5

Breakdown

Who paid Research payments · program years 2022–2025
  1. Moderna TX, Inc. $2,962,830 71 payments
  2. C. R. Bard, Inc. & Subsidiaries $43,840 2 payments
  3. Sanofi Pasteur Inc. $35,963 7 payments
  4. Pfizer Inc. $5,265 17 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $392 1 payment
  6. Boehringer Ingelheim International GmbH $230 5 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,741,809 28 payments
  2. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $1,024,282 29 payments
  3. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $183,845 12 payments
  4. Purest $41,497 1 payment
  5. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $23,963 6 payments
  6. Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. $12,894 2 payments
  7. A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers $12,000 1 payment
  8. A Phase 3 Placebocontrolled Doubleblinded Randomized Study to Evaluate the Efficacy Safety and Tolerability of A Clostridioides Difficile Vaccine in Adults 65 Years of Age and Older $4,712 12 payments
  9. Purest-M $2,343 1 payment
  10. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $621 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record